ストックスクリーナーアプリを入手
2.235
4.53%
-0.105
前日終値:
$2.34
開ける：
$2.36
24時間の取引高:
404.28K
Relative Volume:
0.39
時価総額：
$107.97M
収益：
-
当期純損益:
$-97.22M
株価収益率:
-1.6196
EPS:
-1.38
ネットキャッシュフロー:
$-82.44M
1週間 パフォーマンス:
+6.38%
1か月 パフォーマンス:
+15.75%
6か月 パフォーマンス:
-1.59%
1年 パフォーマンス:
-92.60%
1日の値動き範囲:
$2.23
$2.42
1週間の範囲:
$2.05
$2.525
52週間の値動き範囲:
$1.15
$33.98
Cassava Sciences Inc Stock (SAVA) Company Profile
名前
Cassava Sciences Inc
セクター
電話
512-501-2444
住所
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
SAVA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
2.235 | 117.87M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.61 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.84 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.47 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
668.81 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-26 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-10-08 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-07-01 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-11-16 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2021-07-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
| 2021-04-27 | 開始されました | B. Riley Securities | Buy |
| 2021-02-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-09-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-05-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-15 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-01-10 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Cassava Sciences Inc (SAVA) 最新ニュース
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer - citybiz
Cassava Sciences' Strategic Hire of Joe Hulihan as CMO: A Catalyst for Accelerated Pipeline Development in Neurodegenerative Therapeutics - AInvest
Cassava Sciences appoints Joseph Hulihan as chief medical officer By Investing.com - Investing.com Australia
Former J&J Executive Joins Cassava Sciences to Lead Breakthrough Epilepsy Drug Development - Stock Titan
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. LawsuitSAVA - ACCESS Newswire
Cassava Sciences Announces Positive Preclinical Results - TipRanks
SAVA’s simufilam cuts seizures in TSC mice; first human trial slated H1 2026 | SAVA SEC FilingForm 8-K - Stock Titan
Cassava Sciences and Simufilam: A Groundbreaking Opportunity in TSC-Related Epilepsy - AInvest
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy - The Manila Times
What analysts say about Cassava Sciences Inc. Equity Warrant stockInvest like a pro with expert recommendations - Jammu Links News
What is the risk reward ratio of investing in Cassava Sciences Inc. stockTremendous growth opportunities - Jammu Links News
Why is Cassava Sciences Inc. stock attracting strong analyst attentionUncover the best stocks for explosive growth - Jammu Links News
Is Cassava Sciences Inc. stock overvalued or undervaluedMaximize your returns with portfolio optimization - Jammu Links News
What catalysts could drive Cassava Sciences Inc. stock higher in 2025Consistently high returns - Jammu Links News
Cassava Sciences Inc. Equity Warrant Stock Analysis and ForecastTremendous gains - Jammu Links News
Is it the right time to buy Cassava Sciences Inc. stockPhenomenal capital gains - Jammu Links News
What are the technical indicators suggesting about Cassava Sciences Inc. Equity WarrantFree Trading Strategy Suggestions - Jammu Links News
Is it the right time to buy Cassava Sciences Inc. Equity Warrant stockSuperior stock selection - Jammu Links News
Is Cassava Sciences Inc. Equity Warrant stock overvalued or undervaluedMaximize your portfolio’s growth potential - Jammu Links News
What is the dividend policy of Cassava Sciences Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
What makes Cassava Sciences Inc. Equity Warrant stock price move sharplyExponential wealth increase - Jammu Links News
How does Cassava Sciences Inc. compare to its industry peersHigh-profit stock alerts - Jammu Links News
How does Cassava Sciences Inc. generate profit in a changing economyExponentially increasing returns - Jammu Links News
Should I hold or sell Cassava Sciences Inc. Equity Warrant stock in 2025Maximize returns with smart investment plans - Jammu Links News
What drives Cassava Sciences Inc. Equity Warrant stock priceMarket-leading capital gains - Jammu Links News
What are analysts’ price targets for Cassava Sciences Inc. in the next 12 monthsExceptional profit margins - Jammu Links News
What are analysts’ price targets for Cassava Sciences Inc. Equity Warrant in the next 12 monthsCapitalize on emerging market opportunities - Jammu Links News
What is Cassava Sciences Inc. Equity Warrant company’s growth strategyMaximize returns with effective portfolio management - Jammu Links News
Why is Cassava Sciences Inc. Equity Warrant stock attracting strong analyst attentionExceptional trading performance - Jammu Links News
What catalysts could drive Cassava Sciences Inc. Equity Warrant stock higher in 2025Unstoppable profit momentum - Jammu Links News
When is Cassava Sciences Inc. Equity Warrant stock expected to show significant growthTremendous return rates - Jammu Links News
How strong is Cassava Sciences Inc. company’s balance sheetInvest smarter with high-probability setups - Jammu Links News
What institutional investors are buying Cassava Sciences Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News
What analysts say about Cassava Sciences Inc. stockHigh-profit capital plays - Jammu Links News
SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Cassava Sciences, Inc. to Contact the Firm Today! - ACCESS Newswire
What is Cassava Sciences Inc. company’s growth strategyTremendous growth opportunities - Jammu Links News
Should I hold or sell Cassava Sciences Inc. stock in 2025Smart Portfolio Strategy With High Returns - Jammu Links News
Using Bollinger Bands to evaluate Cassava Sciences Inc. Equity WarrantExpert Verified Stock Trade Ideas Backed by Data - metal.it
Published on: 2025-07-30 22:25:23 - metal.it
Short Covering May Lift Cassava Sciences Inc. in Near TermWeekly Stock Watch With Growth Focus Expanded - metal.it
Why Cassava Sciences Inc. Equity Warrant stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
Is Cassava Sciences Inc. Equity Warrant a Top Dividend Stock to Watch in 2025Daily Chart Pattern Stock Forecast Shows Bullish Setup - metal.it
Relief Rally in Cassava Sciences Inc. Equity Warrant Stock — Can It HoldSecure Return Focused Investment Plan Released - metal.it
Cassava Sciences Inc. Equity Warrant At Decision Level — Rebound or ResistanceBeginner Friendly Stock Selection Guide Updated - metal.it
Published on: 2025-07-29 16:03:06 - metal.it
Cassava Sciences Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingProfit Target Stock Opportunity Monitor Activated - beatles.ru
Published on: 2025-07-29 07:25:41 - beatles.ru
Cassava Sciences Inc (SAVA) 財務データ
収益
当期純利益
現金流量
EPS
Cassava Sciences Inc (SAVA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
0.53%
0.00%
大文字化:
|
ボリューム (24 時間):